Valeant Pharmaceuticals Highlights Taribavirin Phase IIb Data Presentation At European Association For The Study Of Liver (EASL) Annual Meeting
May 15th 2008Drug InformationLiver Disease / Hepatitis
Valeant Pharmaceuticals (NYSE:VRX) announced that results from the treatment week 12 analysis for its Phase IIb clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon, have been accepted for presentation as a late breaker at the European Association for the Study of Liver (EASL) 43rd Annual Meeting in Milan, Italy, April 23-27, 2008.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
